Ovarian cancer treatment: The end of empiricism?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26096019.
- Also identified by DOI 10.1002/cncr.29481 and PMC identifier 4744728.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The diagnosis, investigation, and management of ovarian cancer are in a state of flux-balancing ever rapid advances in our understanding of its biology with 3 decades of clinical trials. Clinical trials that started with empirically driven selections have evolved in an evidence-informed manner to gradually improve outcome. Has this improved understanding of the biology and associated calls to action led to appropriate changes in therapy? In this review, the authors discuss incorporating emerging data on biology, combinations, dose, and scheduling of new and existing agents with patient preferences in the management of women with ovarian cancer.
Medical subject headings
- Evidence-Based Medicine
- Ovarian Neoplasms